Primary decision context: Sleep decisions where circadian-timing evidence and herbal sleep evidence need to be separated rather than blended together.
Quick verdict
No defensible grade-to-grade winner
Only Valerian currently exposes a canonical profile-level evidence grade (B). The comparison should not manufacture a winner while the other side lacks a directly comparable grade.
Melatonin and valerian both appear in sleep conversations, but they should not be treated as equivalent sleep aids. Compare the human evidence, studied dose, preparation, safety, and interaction context recorded for each.
The table below is populated from each ingredient’s canonical runtime record. Missing fields stay visibly missing rather than being filled with mechanism-derived assumptions.
Choose Melatonin if…
•Its human-evidence summary directly addresses the outcome you are researching.
•Its studied dose and formulation context match the form you are actually evaluating.
•You have reviewed its documented safety and interaction constraints rather than choosing on marketing claims alone.
Choose Valerian if…
•Its human-evidence summary directly addresses the outcome you are researching.
•Its studied dose and formulation context match the form you are actually evaluating.
•You have reviewed its documented safety and interaction constraints rather than choosing on marketing claims alone.
Neither may be appropriate if…
The comparison itself does not clear the decision bar
•Neither option has adequate human outcome evidence for the actual decision context: Sleep decisions where circadian-timing evidence and herbal sleep evidence need to be separated rather than blended together.
•The available comparison is driven mainly by mechanism, chemistry, or marketing rather than replicated human outcomes.
•A contraindication, medication interaction, pregnancy concern, or other safety constraint makes unsupervised use inappropriate.
•The relevant studied formulation or dose is materially different from the product or form being considered.
Melatonin vs Valerian: evidence, dose, and safety
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
Melatonin vs Valerian: evidence, dose, and safety
Dimension
Melatonin
Valerian
Evidence strength
Not available in the canonical record.
B
Human evidence
Not available in the canonical record.
Not available in the canonical record.
Studied dose / dose context
Dose-response meta-analysis suggested sleep effects peaking around 4 mg/day and timing about 3 hours before desired bedtime in that analysis; common practice varies. | Oral melatonin; immediate vs prolonged-release and timing should be separated.
Preparation-specific. One standardized extract RCT used an 8-week intervention in adults with sleep complaints; dose must be carried from the actual product/source rather than inferred. | Whole root/rhizome and standardized extracts differ; volatile/unstable constituents create quality-control issues.
Forms / preparation
Not available in the canonical record.
Not available in the canonical record.
Safety
Safety evidence: higher-dose adult trials found more drowsiness, headache, and dizziness without a detected serious-adverse-event increase, but reporting and long-term evidence were limited. Driving, concurrent sedatives, pregnancy, breastfeeding, pediatric use, and chronic use require individualized review.
May improve subjective sleep quality in some people; evidence is mixed and preparation-dependent. | Do not claim proven insomnia treatment; do not merge all valerian extracts. | Upgrade with “what studies used” and “why results conflict” sections.
Dose-response meta-analysis suggested sleep effects peaking around 4 mg/day and timing about 3 hours before desired bedtime in that analysis; common practice varies. | Oral melatonin; immediate vs prolonged-release and timing should be separated.
Forms / preparation
Not available in the canonical record.
Safety
Safety evidence: higher-dose adult trials found more drowsiness, headache, and dizziness without a detected serious-adverse-event increase, but reporting and long-term evidence were limited. Driving, concurrent sedatives, pregnancy, breastfeeding, pediatric use, and chronic use require individualized review.
Preparation-specific. One standardized extract RCT used an 8-week intervention in adults with sleep complaints; dose must be carried from the actual product/source rather than inferred. | Whole root/rhizome and standardized extracts differ; volatile/unstable constituents create quality-control issues.
Forms / preparation
Not available in the canonical record.
Safety
May improve subjective sleep quality in some people; evidence is mixed and preparation-dependent. | Do not claim proven insomnia treatment; do not merge all valerian extracts. | Upgrade with “what studies used” and “why results conflict” sections.
Dose-response meta-analysis indicates melatonin effects depend heavily on timing and dose; adult chronic insomnia evidence is nuanced and not uniformly positive.
Valerian evidence is mixed: older systematic review/meta-analysis found possible subjective sleep/anxiety benefit and no severe adverse events, while umbrella-review evidence remains weak/inconclusive for insomnia. Extract quality and whole-root/rhizome preparation matter.
Read the full profile →Mechanism differences are shown as mechanism context, not as proof of different health benefits. Comparison conclusions should follow human outcome evidence, safety, dose, and formulation data where those fields are available.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.